Physician Views: Assessing Competition in the Idiopathic Pulmonary Fibrosis Market
Late 2014/early 2015 witnessed a flurry of activity in the idiopathic pulmonary fibrosis (IPF) space: Roche's $8.3 billion acquisition of InterMune – providing access to the IPF treatment Esbriet – and subsequent FDA approval of Esbriet and Boehringer Ingelheim's competing therapy Ofev in mid-October.
In January, Ofev was approved for use in the EU, with Esbriet's European label updated in February to reflect a mortality benefit demonstrated in Phase III studies (Esbriet having originally been approved in the region in 2011).
FirstWord Pharma has been tracking developments in the IPF market via a number of previous Physician View polls, focusing on the respective clinical profiles of Esbriet and Ofev, anticipated usage in the US market and launch of Ofev in the EU market.
With Esbriet and Ofev having now been available in the US market for over six months, and with the European IPF market evolving with the availability of Boehringer Ingelheim's product and new labelling for Esbriet, we are asking pulmonologists based in the US and EU5 markets to provide their initial assessment of these two breakthrough drugs for IPF.
Specifically we are asking pulmonologists...
Of the newer treatments approved for IPF – Esbriet (pirfenidone) and Ofev (nintedanib) – which is your favoured drug (the one you prescribe the most) and why?
In 12 months' time, to what percentage of eligible IPF patients would you anticipate prescribing Ofev to?
In January, Ofev was approved for use in the EU, with Esbriet's European label updated in February to reflect a mortality benefit demonstrated in Phase III studies (Esbriet having originally been approved in the region in 2011).
FirstWord Pharma has been tracking developments in the IPF market via a number of previous Physician View polls, focusing on the respective clinical profiles of Esbriet and Ofev, anticipated usage in the US market and launch of Ofev in the EU market.
With Esbriet and Ofev having now been available in the US market for over six months, and with the European IPF market evolving with the availability of Boehringer Ingelheim's product and new labelling for Esbriet, we are asking pulmonologists based in the US and EU5 markets to provide their initial assessment of these two breakthrough drugs for IPF.
Specifically we are asking pulmonologists...
Of the newer treatments approved for IPF – Esbriet (pirfenidone) and Ofev (nintedanib) – which is your favoured drug (the one you prescribe the most) and why?
- Esbriet – based on clinical profile
- Esbriet – based on patient access programme
- Esbriet – based on price
- Esbriet – Other (please state)
- Ofev – based on clinical profile
- Ofev – based on patient access programme
- Ofev – based on price
- Ofev – other (please state)
- I use both products equally
- I have no choice in selecting either product but prefer Esbriet
- I have no choice in selecting either product but prefer Ofev
- Not at all satisfied
- Slightly satisfied
- Moderately satisfied
- Very satisfied
- Completely satisfied
- Not at all satisfied
- Slightly satisfied
- Moderately satisfied
- Very satisfied
- Completely satisfied
In 12 months' time, to what percentage of eligible IPF patients would you anticipate prescribing Ofev to?
